[EBH]

FYI

Beast 1 a socio-economic world government

Beast 2 Internet? Specifically the Tech giants/social media

There's lots happening and moving incredibly fast. This short video just sliced and diced where the world is heading ...

[EBH]

PharmaJet and Diomics Partner on SARS-CoV-2 Immune Response Monitoring

https://www.biospace.com/article/releases/pharmajet-and-diomics-partner-on-sars-cov-2-immune-response-monitoring/

GOLDEN, Colo.—(BUSINESS WIRE)— PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Tropis® Needle-free Injection System will be used by Diomics, a San Diego-based biotech company, to deliver a biopolymer to detect the formation of an immune response to a SARS-CoV-2 protein. The company was awarded over $2 million by the Department of Defense to accelerate testing of its Diocheck™ system and is expected to begin human clinical trials in December 2020.

The Diocheck SARS-CoV-2 Visual Immune Response Indicator provides a simple, universal way to continually monitor a person’s immune response status to COVID-19 over an extended period of time, eliminating the need for more frequent testing. Diomics’ proprietary biopolymer material, Diomat™, containing a COVID-19 antigen, will be injected under the skin with the PharmaJet Tropis device. The skin reaction at the injection site will act as an indicator of an immune response against COVID-19 infection, showing whether a person has been exposed to the virus, and whether they need to get tested and take precautions to avoid infecting others. This procedure is readily scalable and could provide consistent, accurate ongoing monitoring of the immunity status of essential front-line workers, including military, healthcare, transportation, and public safety personnel.

“We are pleased to be collaborating with Diomics on this immune response monitoring program. Our Needle-free design features a precise and consistent method of delivery to ensure accuracy, in addition to its proven ease of administration in mass immunization campaigns,” commented Chris Cappello, President and CEO, PharmaJet.

For more information about PharmaJet visit www.pharmajet.com.

[ransomnote]

ransomnote: *sigh* A mark....from 'nanobeads'

"But, they are developing injectables that leave a "mark" on the skin for over a year."

ransomnote: But the Tribulation is 7 years, even though the days will be shortened....

[mewzilla]

Diomics.

Just checked, the company is incorporated in Delaware.

Go figure.

[grey_whiskers]

Forearm? Not forehead or hand?

[bitt]

p

[MNDude]

I propose a 3 digit number on the forehead.